While the specific ratio of Sativa to Indica technically falls within the ‘hybrid’ label, patients generally agree the effects fall mostly on the Indica side. Derived from the West Coast classic Sweet Kush, Lyra has a particularly sweet flavor and aroma with hints of earthy and fruity tones. The immediate effect is cerebral, but that quickly fades into bodily deep relaxation. The effects are described as creativity inducing while delivering a healthy dose of euphoria.
Fluent products are not intended to diagnose, treat, cure or prevent any disease and have not been evaluated by the Food and Drug Administration. Consult your physician or provider before starting or stopping any medical cannabis product.
Prices for 30, 50, and 70 days of product supply are based on the minimum dose of product and will vary per patient depending on their individual intake habits and dosing.
Each vaporizer 450 mg cartridge contains 3 mg THC/inhalation
Approx: 150 inhalations per cartridge
“Vaping” is short for “vaporization”. Effects are felt immediately and unlike smoking, no combustion or burning takes place. Portable vaporizers are very discreet, as vapor dissipates quickly with minimal odor.
Patients are recommended to initiate treatment on the evening of Day 1 with 1-3 inhalation sessions. Each session consists of 1-2 draws that are relatively shallow (1-3 seconds) and held for about 5 seconds before exhaling. After 5-10 minutes, patients reassess symptoms.
If symptoms have improved or subsided, no additional sessions are needed and patients take the next dose on the morning of Day 2. Relief for patients with chronic neuropathic pain who have not responded adequately to other pain medication.
Lyra is contraindicated in patients:
• with hypersensitivity to cannabinoids (e.g., THC or CBD) or to any of the inert ingredients in Lyra;
• with a significant history of cardiovascular disease;
• with an active or previous psychotic or active mood or anxiety disorder; and
• who are pregnant, planning to become pregnant, or are breastfeeding.